Migraine prophylaxis-all just antibodies? Medical and nonmedical migraine preventive treatment in times of CGRP antibodies

被引:0
|
作者
Hamann, Till [1 ]
Kamm, Katharina [2 ]
Kropp, Peter [3 ]
Rimmele, Florian [1 ]
Juergens, Tim Patrick [1 ]
机构
[1] Univ Med Rostock, Klin & Poliklin Neurol, Kopfschmerzzentrum Nord Ost, Gehlsheimer Str 20, D-18147 Rostock, Germany
[2] Ludwig Maximilians Univ Munchen, Klinikum Univ Munchen, Neurol Klin & Poliklin, Oberbayr Kopfschmerzzentrum, Munich, Germany
[3] Univ Med Rostock, Inst Med Psychol & Med Soziol, Kopfschmerzzentrum Nord Ost, Rostock, Germany
来源
SCHMERZ | 2020年 / 34卷 / 06期
关键词
Receptors; calcitonin gene-related peptide; Immunotherapy; Analgesics; Prevention; Medication overuse; CORTICAL SPREADING DEPRESSION; PREVALENCE; TOPIRAMATE; HEADACHE; BURDEN;
D O I
10.1007/s00482-020-00500-x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background Migraine is a frequently underdiagnosed disease that is associated with a high burden on affected patients. There are a variety of prophylactic treatment options available, that have been expanded with the introduction of the CGRP-(receptor-)antibodies. Objectives Status of pharmacologic and nonpharmacologic preventive treatment in migraine therapy. Methods Analysis and evaluation of internationally published articles concerning preventive treatment of episodic and chronic migraine. Results There are many approved medications for migraine prophylaxis with different evidence. The possibilities were further expanded with CGRP antibodies. Comparative studies of the new antibodies with previous prophylactic drugs have not yet been published, so it's unclear whether the antibodies are therapeutically superior. What should be emphasized is their rapid onset of action and their good tolerance. Basically, an individual choice of prophylaxis, which is based on affectedness, comorbidities and comedication, makes sense. In addition, a combination with nondrug measures is always mandatory. Conclusions A variety of medicinal and non-medicinal measures are available for the treatment of migraine, which should be used multimodally.
引用
收藏
页码:476 / 485
页数:10
相关论文
共 50 条
  • [21] CGRP antibodies: the Holy Grail for migraine prevention?
    Pascual, Julio
    LANCET NEUROLOGY, 2015, 14 (11): : 1066 - 1067
  • [22] CGRP Monoclonal Antibodies for Migraine: Rationale and Progress
    Yuan, Hsiangkuo
    Lauritsen, Clinton G.
    Kaiser, Eric A.
    Silberstein, Stephen D.
    BIODRUGS, 2017, 31 (06) : 487 - 501
  • [23] Effectiveness of anti-CGRP monoclonal antibodies in the preventive treatment of migraine: A prospective study of 63 patients
    Castrillo, Ana
    Mendoza, Amelia
    Caballero, Lorena
    Cerdan, Debora
    Rodriguez, Maria Fernanda
    Guerrero, Pilar
    Tabernero, Cesar
    Ferrero, Marta
    Benito, Ines
    Marin, Laura
    Duarte, Jacinto
    MEDICINA CLINICA, 2023, 160 (08): : 341 - 346
  • [24] Use of new Antibodies in Migraine Prophylaxis
    不详
    HNO, 2020, 68 (06) : 406 - 406
  • [25] Use of new Antibodies in Migraine Prophylaxis
    不详
    HNO, 2020, 68 (04) : 271 - 271
  • [26] Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Migraine
    Hennessy, Elise
    Salim, Amira
    Biswas, Sudipa
    Suneja, Aarushi
    Mays, Maryann
    Ahmed, Zubair
    Mata, Ignacio
    NEUROLOGY, 2023, 100 (17)
  • [27] Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives
    De Matteis, Eleonora
    Guglielmetti, Martina
    Ornello, Raffaele
    Spuntarelli, Valerio
    Martelletti, Paolo
    Sacco, Simona
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2020, 20 (06) : 627 - 641
  • [28] Synergism of anti-CGRP monoclonal antibodies and onabotulinumtoxinA in the treatment of migraine
    Hennessy, E.
    Salim, A.
    Biswas, S.
    Sonneborn, C.
    Hogue, O.
    Suneja, A.
    Mays, M.
    Ahmed, Z.
    Mata, I
    HEADACHE, 2023, 63 : 170 - 171
  • [29] CGRP Monoclonal Antibodies: Targeted Migraine Treatment and Cardiovascular Safety Profile
    Boldig, Kimberly
    Butala, Nitin
    ANNALS OF NEUROLOGY, 2020, 88 : S148 - S149
  • [30] NEW OPTIONS FOR MIGRAINE TREATMENT: FOCUS ON CGRP-BLOCKING ANTIBODIES
    Dux, M. J.
    Messlinger, K. B.
    DRUGS OF THE FUTURE, 2015, 40 (09) : 589 - 599